¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptors, Estrogen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® estrogen ÇÑ±Û ¿¡½ºÆ®·Î°Õ
¼³¸í   
  ³­¼Ò¾È¿¡ Àִ ³­Æ÷¿¡¼­ ºÐºñµÇ´Â ³­Æ÷È£¸£¸óÀÇ ÃÑĪ. ¿©Æ÷È£¸£¸ó, ¹ßÁ¤ È£¸£¸óÀ̶ó°íµµ ÇÑ´Ù. ¿¡½ºÆ®·Î°ÕÀ̶õ »ý¹°ÇÐÀûÀΠ¸íĪÀ̸砵¿¹°ÀÇ ¹ßÁ¤ÀÛ¿ë ¿Ü¿¡ ¿©·¯ °¡Áö ÀÛ¿ëÀ» Áö´Ñ ¹°ÁúÀÇ ÃÑĪÀÌ´Ù. »ç¶÷¿¡´Â 20Á¾ ÀÌ»óÀÇ ¿¡½ºÆ®·Î°ÕÀÇ Á¾·ù°¡ ÀÖÁö¸¸, ±×Áß¿¡¼­µµ estrone, estradiol, estriolÀÇ 3°¡Áö°¡ °¡Àå Áß¿äÇÏ´Ù. ¿¡½ºÆ®·Î°ÕÀº ºñÀӽŽÿ¡´Â ¿©Æ÷È£¸£¸óÀÇ Á¶Àý¿¡ ÀÇÇØ¼­, ÁַΠ³­¼Ò¿¡¼­ »ý¼ºµÇ¸ç, ÀӽŽÿ¡´Â ÁַΠŹݿ¡¼­ ¸¸µé¾îÁöÁö¸¸, estriolÀº Å¾ÆÀÇ ºÎ½Å°ú Å¹ÝÀÇ ÇÕµ¿ÀÛ¿ë¿¡ ÀÇÇØ¼­ ¸¸µç´Ù. »ç¶÷¿¡°Ô À־ ¿¡½ºÆ®·Î°ÕÀÇ ÁֵȠÀÛ¿ëÀº ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù.
  
  1. Á¦ 2Â÷ ¼ºÂ¡ÀÇ ¹ßÇö. 2. ³»¼º±â, Áú, ¿Ü¼º±âÀÇ ¹ßÀ°ÃËÁø 3. Àڱ󻸷 ¹× ¼º±â »óÇÇÀÇ Áõ½Ä 4. ¹è¶õ±â¿¡ ÀÚ±ÃÀÇ ÀÔ±¸ÀΠ¸ñ¿¡ Á¡¾×À» Áõ·®½ÃÄÑ Á¤ÀÚÀÇ Åë°ú¼ºÀ» ÁÁ°Ô ÇÑ´Ù. 5. ÀӽŽÿ¡ ¼º±â¿Í À¯¹æ µî¿¡ Àӽżº º¯È­¸¦ ÀÏÀ¸Å²´Ù. 6. ¼º±âÀÇ ±ÙÀ°À» Áõ½Ä½ÃÄÑ ¿îµ¿¼ºÀ» Áõ°¡½ÃŲ´Ù. 7. ´Ü¹éÁú ÁöÁú, ¹«±âÁú µîÀÇ ¹°Áú´ë»ç³ª ¿©·¯ °¡Áö È¿¼ÒÀÇ ÀÛ¿ë¿¡ ¿µÇâÀ» ÁØ´Ù. 8. ¹è¶õ°ú »ý¸® ÁÖ±âÀÇ À¯Áö¿¡ °ü¿©ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • conjugated estrogen
    °áÇÕ¿¡½ºÆ®·Î°Õ
  • estrogen
    ¿¡½ºÆ®·Î°Õ
  • estrogen challenge test
    ¿¡½ºÆ®·Î°ÕºÎÇϰ˻ç
  • estrogen cream
    ¿¡½ºÆ®·Î°ÕÅ©¸²
  • estrogen receptor
    ¿¡½ºÆ®·Î°Õ¼ö¿ëü
  • estrogen replacement therapy
    ¿¡½ºÆ®·Î°Õ´ëÄ¡¿ä¹ý
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estrogen cream
    ¿¡½ºÆ®·Î°ÕÅ©¸²
  • estrogen
    1.¿©¼ºÈ£¸£¸ó, 2.¿¡½ºÆ®·Î°Õ
  • estrogen challenge test
    ¿©¼ºÈ£¸£¸óºÎÇϰ˻ç
  • estrogen replacement therapy
    ¿©¼ºÈ£¸£¸ó´ëü¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • conjugated estrogen
    °áÇÕ¿¡½ºÆ®·Î°Õ
  • estrogen
    ¿©¼ºÈ£¸£¸ó, ¿¡½ºÆ®·Î°Õ
  • estrogen window hypothesis
    ¿¡½ºÆ®·Î°Õâ°¡¼³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • GABA A receptors
    GABA A ¼ö¿ëü(áôé»ô÷)
  • GABA receptors
    GABA ¼ö¿ëü(áôé»ô÷)
  • GABAB receptors
    GABA B ¼ö¿ëü(áôé»ô÷)
  • H1 receptors
    H1¼ö¿ëü(â¥é»ô÷)
  • HT receptors
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î¼ö¿ëü
  • HT2 receptors, action of hallucinogens
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î2¼ö¿ëü
  • Hair follicle receptors
    ¸ð³¶¼ö¿ëü(Ù¾Ò¥â¥é»ô÷)
  • Hair receptors
    ¸ð¼ö¿ëü(Ù¾â¥é»ô÷)
  • Heat receptors
    ¿­¼ö¿ëü(æðâ¥é»ô÷)
  • Histamine receptors
    È÷½ºÅ¸¹Î¼ö¿ëü
  • Immunoglobulin adhesion receptors
    ¸é¿ª±Û·ÎºÒ¸° ºÎÂø(ݾó·)¼ö¿ëü
  • Irritant receptors, ventilatory responses , ventilatory responses
    Àڱؼö¿ëü(í©Ð½áôé»ô÷), È£Èí¹ÝÀÀ(û¼ýåÚãëë)
  • J receptors, ventilatory responses mediated
    J ¼ö¿ëü(áôé»ô÷), È£Èí¹ÝÀÀ(û¼ýåÚãëë)
  • Kainate receptors
    Ä«À̳×ÀÌÆ®¼ö¿ëü(áôé»ô÷)
  • Kappa receptors
    Ä«ÆÄ¼ö¿ëü(áôé»ô÷)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atrial receptors
    (½É)¹æ¼ö¿ëü(¡­áôé»ô÷)
  • atrial receptors
    ½É¹æ¼ö¿ëü(¡­áôé»ô÷).
  • down-regulation (of receptors)
    (¼ö¿ëü)ÇÏÇâÁ¶Àý.
  • down-regulation (of receptors)
    ¼ö¿ëü(áôé»ô÷)ÇÏÇâÁ¶Àý(ù»ú¾ðàï½).
  • presynaptic receptors
    ½Å°æÁ¢ÇÕÀü ¼ö¿ëü
  • receptors
  • conjugated estrogen
    °áÇÕ¿¡½ºÆ®·Î°Õ.
  • estrogen
    ¿¡½ºÆ®·Î°Õ, ³­Æ÷È£¸£¸ó
  • estrogen
    ¿¡½ºÆ®·Î°Õ, ³­Æ÷È£¸£¸ó
  • estrogen
    ¸®¿¡½ºÆ®·Î°Õ, ³­Æ÷(Õ°øà)È£¸£¸ó.
  • estrogen
    ¿¡½ºÆ®·Î°Õ
  • estrogen
    ¿¡½ºÆ®·Î°Õ.
  • estrogen
    ¸®¿¡½ºÆ®·Î°Õ, ³­Æ÷È£¸£¸ó.
  • estrogen phase
    ¿¡½ºÆ®·Î°Õ±â(Ñ¢).
  • estrogen phase
    ¿¡½ºÆ®·Î°Õ±â.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estrogen
    ¿¡½ºÆ®·ÎÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estrogen
    ¿¡½ºÆ®·Î°Õ, ³­Æ÷È£¸£¸ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
AChRs Acetylcholine Receptors
RA radioactive; ragocyte; ragweed antigen; rapidly adapting [receptors]; reactive arthritis; reciprocal...
E1 Estrone; Æó°æÈÄ ÁÖµÈ Estrogen
E2 Estradiole; Æó°æÀü ÁÖµÈ Estrogen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ER, PR Estrogen and progesterone receptors
AR Alpha1-adrenergic receptors
alpha1-ARs Alpha1-adrenergic receptors
beta 2AR Beta 2-adrenergic receptors
CR1 C3b-C4b receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • conjugated estrogen
    °áÇÕ ¿¡½ºÆ®·Î°Õ
  • estrogen
    ¿©¼º È£¸£¸ó
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
estrogen <endocrinology, hormone> A generic term for oestrus producing steroid compounds, the female sex hormones.
In humans, oestrogen is formed in the ovary, possibly the adrenal cortex, the testis and the foetoplacental unit, it has various functions in both sexes. It is responsible for the development of the female secondary sex characteristics and during the menstrual cycle it acts on the female genitalia to produce an environment suitable for the fertilization, implantation and nutrition of the early embryo.
Oestrogen is used in oral contraceptives and as a palliative in cancer of the breast after menopause and cancer of the prostate, other uses include the relief of the discomforts of menopause, inhibition of lactation and treatment of osteoporosis, threatened abortion and various functional ovarian disorders.
(18 Nov 1997)
estrogen 2-hydroxylase <enzyme> Same enzyme for hydroxylation in 2 or 4 position
Registry number: EC 1.14.99.-
Synonym: estrogen 4-hydroxylase, ethinylestradiol 2-hydroxylase
(26 Jun 1999)
adrenergic receptors Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents.
Synonym: adrenoceptor, adrenoreceptors.
(05 Mar 2000)
alpha-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles.
(05 Mar 2000)
ANP clearance receptors Cell surface proteins that bind atrial natriuretic peptide and ANP fragments without initiating biological action.
(05 Mar 2000)
ANP receptors Cell surface receptors for atrial natriuretic peptide that have a single transmembrane spanning element; these have integral kinase and guanylate cyclase domains.
(05 Mar 2000)
B-cell antigen receptors In the primary immune response immunoglobulin D and monomeric immunoglobulin M are the B-cell antigen receptors. On memory B-cells, other immunoglobulin molecules can serve as antigen receptors.
(05 Mar 2000)
beta-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as propranolol, to block only some adrenergic receptor's and of other agents, such as isoproterenol, to activate only the same adrenergic receptor's. Such receptor's are designated as beta-receptors. Their activation results in physiological responses such as increases in cardiac rate and force of contraction (b1), and relaxation of bronchial and vascular smooth muscle (b2).
(05 Mar 2000)
mannose-6-phosphate receptors Receptors in Golgi apparatus to which newly synthesised proteins that are destined to enter lysosomes bind.
(05 Mar 2000)
receptors, adrenergic Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction.
(12 Dec 1998)
receptors, adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors. The alpha-beta distinction was originally based on cellular effects of receptor activation but now relies on the relative affinities for certain synthetic ligands. Alpha-adrenergic receptors are further subdivided into several subclasses based on studies of endogenous and cloned receptors.
(12 Dec 1998)
receptors, adrenergic, alpha-1 A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-1 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist phenylephrine and the antagonist prazosin. They are widespread, with clinically important concentrations in the liver, the heart, vascular, intestinal, and genitourinary smooth muscle, and the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, alpha-2 A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-2 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist clonidine and the antagonist yohimbine. They are found on pancreatic beta cells, platelets, and vascular smooth muscle, as well as both pre- and postsynaptically in the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, beta One of the two major pharmacologically defined classes of adrenergic receptors. The alpha-beta distinction was originally based on the cellular effects of receptor activation but now relies on the relative affinities for characteristic synthetic ligands. Beta adrenergic receptors are further subdivided based on information from endogenous and cloned receptors.
(12 Dec 1998)
receptors, adrenergic, beta-1 A subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-1 adrenergic receptors are equally sensitive to epinephrine and norepinephrine and bind the agonist dobutamine and the antagonist metoprolol with high affinity. They are found in the heart, juxtaglomerular cells, and in the central and peripheral nervous systems.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Receptors, Estrogen - »õâ Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
    Synonyms : Estrogen Nuclear Receptor, Estrogen Receptor Type I, Estrogen Receptor Type II, Estrogen Receptors Type I, Estrogen Receptors Type II, Receptor, Estrogen Nuclear, Receptors, Estrogen, Type I, Receptors, Estrogen, Type II, Nuclear Receptor, Estrogen
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • estrogen
    ¹ßÁ¤È£¸£¸ó
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á